Antibody therapeutics player ImmunitoAI raises $6.1 M from led by Ashish Kacholia, others

Bengaluru-based immunitoAI has raised USD 6.1 million in Series A funding, led by investor Ashish Kacholia. The funding round also saw participation from new investors like 3one4 Capital and AC Ventures, with participation from existing investors such as pi Ventures and Anicut Capital.Founded in 2020, immunitoAI designs antibody sequences for any target antigen using artificial intelligence. The startup intends to generate revenue by selling intellectual property, developing custom antibodies, and eventually bringing its own drugs to market.The company plans to use the capital to develop new antibody therapeutics, aiming to reduce the typical 4-5 year development time to 11-12 months using its generative AI platform.